ACHC INVESTOR NOTICE: Acadia Healthcare Company, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

SAN DIEGO, Nov. 21, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) publicly traded securities between February 28, 2020 and September 26, 2024, inclusive (the "Class Period"), have until Monday, December 16, 2024 to seek appointment as lead plaintiff of the Acadia Healthcare class action lawsuit. Captioned Kachrodia v. Acadia Healthcare Company, Inc., No. 24-cv-01238 (M.D. Tenn.), the Acadia Healthcare class action lawsuit charges Acadia Healthcare as well as certain of Acadia Healthcare's top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Acadia Healthcare class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-acadia-healthcare-company-inc-class-action-lawsuit-achc.html 

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.

CASE ALLEGATIONS: Acadia Healthcare provides behavioral healthcare services.

The Acadia Healthcare class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Acadia Healthcare's business model centered on holding vulnerable people against their will in Acadia Healthcare's facilities, including in cases where it was not medically necessary to do so; (ii) while in Acadia Healthcare facilities, many patients were subjected to abuse; and (iii) Acadia Healthcare deceived insurance providers into paying for patients to stay in Acadia Healthcare's facilities when it was not medically necessary.

The Acadia Healthcare class action lawsuit further alleges that on September 1, 2024, The New York Times published an article entitled "How a Leading Chain of Psychiatric Hospitals Traps Patients," which revealed that The New York Times's "investigation found that some of that success was built on a disturbing practice: Acadia has lured patients into its facilities and held them against their will, even when detaining them was not medically necessary." On this news, the price of Acadia Healthcare stock fell more than 4%, according to the complaint.

Then, on September 27, 2024, the Acadia Healthcare class action lawsuit further alleges that Acadia Healthcare revealed that "[o]n September 24, 2024, Acadia Healthcare . . . received a voluntary request for information from the United States Attorney's Office for the Southern District of New York as well as a grand jury subpoena from the United States District Court for the Western District of Missouri (W.D.Mo.) related to its admissions, length of stay and billing practices," further disclosing that "Acadia anticipates receiving similar document requests from the U.S. Securities and Exchange Commission and may receive additional document requests from other government agencies." On this news, the price of Acadia Healthcare stock fell more than 16%, according to the Acadia Healthcare class action lawsuit.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Acadia Healthcare publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Acadia Healthcare class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Acadia Healthcare class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Acadia Healthcare class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Acadia Healthcare class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/achc-investor-notice-acadia-healthcare-company-inc-investors-with-substantial-losses-have-opportunity-to-lead-securities-class-action-lawsuit-302310724.html

SOURCE Robbins Geller Rudman & Dowd LLP